The introduction of BRAF inhibitors (BRAFi), such as vemurafenib and dabrafenib, as standard of care for the treatment of BRAF‐mutant melanoma has significantly improved the response rate among patients (Chapman et al, 2011). The gene discussed is BRAF; the disease is melanoma.